Mostrando 10 resultados de: 17
Filtros aplicados
Publisher
Pharmacogenomics Journal(5)
European Journal of Clinical Pharmacology(3)
Pharmacogenomics(2)
European Journal of Drug Metabolism and Pharmacokinetics(1)
Expert Opinion on Drug Metabolism and Toxicology(1)
Área temáticas
Farmacología y terapéutica(13)
Bioquímica(11)
Enfermedades(5)
Fisiología humana(4)
Cultura e instituciones(3)
CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
ArticleAbstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in CaPalabras claves:CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogeneticsAutores:Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., LARES, Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusGenetic variability of CYP2C9∗2 and CYP2C9∗3 in seven indigenous groups from Mexico
ArticleAbstract: Aim: CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphiPalabras claves:allele frequency, CYP2C9, hypoglycemic therapy, Mexican indigenous, pharmacogenetics, polymorphismAutores:Adrián LLerena, García-Rodríguez M., Granados-Silvestre M., Menjívar M., Ortiz-López M.G., Peña-Espinoza B., Rivera-Santiago C., Sánchez-Pozos K.Fuentes:scopusIncreased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
Conference ObjectAbstract: In the present study, we aimed to analyze the potential relevance of the polymorphism in the promotePalabras claves:5-HTTLPR, CYP2C9, genetic polymorphism, major depression, SerotoninAutores:Adrián LLerena, Cáceres M.C., Cobaleda J., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusInfluence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico
ArticleAbstract: We previously documented the lowest frequency of CYP2C9*2 in Mexican indigenous Tepehuanos followedPalabras claves:ancestral components, CYP2C9, Mexican indigenous, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Galaviz-Hernandez C., Lazalde-Ramos B.P., Licinio J., Martínez-Fierro M.L., Martínez-Sevilla V.M., Rangel-Villalobos H., Salazar-Flores J., Sosa-Macías M.G., Wong M.L.Fuentes:scopusInterethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
ArticleAbstract: The aims of this study were to evaluate the diclofenac metabolism in Hispanics from Cuba and Spain aPalabras claves:CYP2C9, Diclofenac, Environmental factors, Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Cobaleda J., Dorado P., González I., Penãs-Lledó E.M., Pérez B.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusQTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
ArticleAbstract: The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, haPalabras claves:9-hydroxy-risperidone, CYP2C9, CYP2D6, QTc, RisperidoneAutores:Adrián LLerena, Berecz R., De La Rubis A., Dorado P.Fuentes:scopusRelationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers
ArticleAbstract: Purpose: CYP2C8 seems to be involved in diclofenac 5-hydroxylation, while, in vitro, the 4′-hydroxylPalabras claves:CYP2C8, CYP2C9, Diclofenac, Healthy volunteers, SpaniardsAutores:Adrián LLerena, Cáceres M.C., Cavaco I., Dorado P., Piedade R., Ribeiro V.Fuentes:scopus